rbtfl.

industry / capital-markets

관점별 · 1 takes across the edition

Frames the round as the second-largest biotech financing ever, total funding now ~$2.6B, and notes Hassabis's revised target: first in-house candidates in human trials by end-2026 after he conceded he had 'misspoke' on the earlier 2025 date.

“AI-fueled Isomorphic bags $2.1B, the second largest biotech round ever.”